Richard Mancco
About Richard Mancco
Richard Mancco is the Director of Business Development Analytics for Hematology & CAR-T at Bristol Myers Squibb, with a background in finance and mechanical engineering from the University of Pennsylvania and MIT.
Company
Richard Mancco currently works at Bristol Myers Squibb in Princeton, New Jersey, United States. He holds the position of Director in the Business Development Analytics department, specifically focusing on Hematology and CAR-T therapies. His responsibilities include leading cross-functional teams, mentoring junior analysts and interns, and developing strategic roadmaps for CAR-T therapies.
Title
Richard Mancco is the Director of Business Development Analytics for Hematology and CAR-T at Bristol Myers Squibb. In this role, he has led initiatives in strategic planning and market forecasting, contributing to significant advancements in CAR-T therapy development.
Education and Expertise
Richard Mancco holds a Master of Business Administration (M.B.A.) with a concentration in Finance and Entrepreneurial Management from the University of Pennsylvania - The Wharton School, which he completed between 2016 and 2018. He also has a Bachelor of Science in Mechanical Engineering and Management Science from the Massachusetts Institute of Technology, completed between 2007 and 2011.
Background
Before joining Bristol Myers Squibb, Richard Mancco had experience in both business development and investment. He served as Director of Business Development at Pandorum Technologies Pvt. Ltd., Investment Associate in the Venture Capital Team at SUN Group, MBA Intern in the Investment Strategy Group at Vanguard, Senior Analyst at Capital One, and Consultant and Senior Analyst at SRA International.
Achievements
Richard Mancco's notable achievements include leading the development of a strategic roadmap for CAR-T therapies, securing a major partnership deal for hematology research, and publishing a white paper on the economic impact of CAR-T therapies. He has also developed a proprietary analytics model for forecasting market trends in the hematology sector and has presented at the 2023 Annual Hematology Conference on CAR-T cell therapy advancements. He received the 'Innovator of the Year' award at Bristol Myers Squibb.